We found that treatment with P021 from prenatal day 8 till PND 21 prevented cognitive deficits at 4 months, reduced tau and amyloid pathologies at 22 months, and decreased postsynaptic deficits and neuroinflammation in the brain at both 4 and 22 months in 3xTg-AD mice. This evidence concerns the gene MAPT and Cognitive impairment.